Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1980 1
1984 3
1985 2
1986 2
1988 5
1989 2
1990 9
1991 5
1992 8
1993 6
1994 5
1995 18
1996 17
1997 11
1998 10
1999 12
2000 15
2001 17
2002 23
2003 21
2004 26
2005 31
2006 39
2007 67
2008 75
2009 80
2010 53
2011 55
2012 65
2013 89
2014 68
2015 106
2016 135
2017 138
2018 124
2019 128
2020 182
2021 216
2022 251
2023 140
2024 60

Text availability

Article attribute

Article type

Publication date

Search Results

2,026 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %, %, %
The following terms were not found in PubMed: 22alefacept, 22allogenic, 22chronic
Page 1
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications.
Singh R, Koppu S, Perche PO, Feldman SR. Singh R, et al. Int J Mol Sci. 2021 Nov 26;22(23):12793. doi: 10.3390/ijms222312793. Int J Mol Sci. 2021. PMID: 34884596 Free PMC article. Review.
Plaque psoriasis', the most prevalent subtype of psoriasis, pathogenesis primarily involves cytokines TNF-alpha, IL-17, and IL-23. Pustular psoriasis', an uncommon variant, pathogenesis involves a mutation in IL-36RN. ...
Plaque psoriasis', the most prevalent subtype of psoriasis, pathogenesis primarily involves cytokines TNF-alpha, IL-17, …
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Yang K, Oak ASW, Elewski BE. Yang K, et al. Am J Clin Dermatol. 2021 Mar;22(2):173-192. doi: 10.1007/s40257-020-00578-0. Am J Clin Dermatol. 2021. PMID: 33301128 Free PMC article. Review.
Psoriasis is a common inflammatory skin disease with multiple comorbidities, including psoriatic arthritis and coronary artery disease, that can severely impact an individual's quality of life and daily functioning. ...Among these, inhibitors of interleukin-23 (e.g., ustek …
Psoriasis is a common inflammatory skin disease with multiple comorbidities, including psoriatic arthritis and coronary artery diseas …
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C. Warren RB, et al. Br J Dermatol. 2021 Jan;184(1):50-59. doi: 10.1111/bjd.19341. Epub 2020 Sep 6. Br J Dermatol. 2021. PMID: 32594522 Free PMC article. Clinical Trial.
BACKGROUND: Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin-23 and interleukin-17A, respectively, and are effective in a …
BACKGROUND: Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatmen …
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, Albrecht L, Gooderham M, Chen M, Paris M, Wang Y, Callis Duffin K. Stein Gold L, et al. J Am Acad Dermatol. 2022 Jan;86(1):77-85. doi: 10.1016/j.jaad.2021.07.040. Epub 2021 Jul 31. J Am Acad Dermatol. 2022. PMID: 34343599 Clinical Trial.
BACKGROUND: Patients with mild-to-moderate psoriasis may have substantial quality-of-life impairment. OBJECTIVE: To evaluate apremilast 30 mg twice daily for mild-to-moderate psoriasis. METHODS: Phase 3, double-blind, placebo-controlled study in adults with mild-to- …
BACKGROUND: Patients with mild-to-moderate psoriasis may have substantial quality-of-life impairment. OBJECTIVE: To evaluate apremila …
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.
Strober B, Stein Gold L, Bissonnette R, Armstrong AW, Kircik L, Tyring SK, Piscitelli SC, Brown PM, Rubenstein DS, Tallman AM, Lebwohl MG. Strober B, et al. J Am Acad Dermatol. 2022 Oct;87(4):800-806. doi: 10.1016/j.jaad.2022.06.1171. Epub 2022 Jun 27. J Am Acad Dermatol. 2022. PMID: 35772599 Free article.
BACKGROUND: Tapinarof cream 1% once daily, an aryl hydrocarbon receptor-modulating agent, was significantly more efficacious than vehicle and well tolerated in two 12-week phase 3 trials in adults with mild to severe plaque psoriasis. OBJECTIVE: To assess long-term …
BACKGROUND: Tapinarof cream 1% once daily, an aryl hydrocarbon receptor-modulating agent, was significantly more efficacious than vehicle an …
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C. Bodemer C, et al. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):938-947. doi: 10.1111/jdv.17002. Epub 2021 Jan 19. J Eur Acad Dermatol Venereol. 2021. PMID: 33068444 Free PMC article. Clinical Trial.
OBJECTIVES: Here, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with severe chronic plaque psoriasis over one year are reported. METHODS: In this multicentre, double-blind study (NCT02471144), pa …
OBJECTIVES: Here, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with …
Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
Woods RH. Woods RH. Br J Clin Pharmacol. 2023 Aug;89(8):2386-2395. doi: 10.1111/bcp.15581. Epub 2022 Nov 15. Br J Clin Pharmacol. 2023. PMID: 36321844
AIMS: The interleukin-23 (IL-23) inhibitor risankizumab was recently approved for the treatment of moderate-to-severe plaque psoriasis in the United States. Low rates of cerebrovascular accident (CVA) were observed in risankizumab-treated patients during clinical tr …
AIMS: The interleukin-23 (IL-23) inhibitor risankizumab was recently approved for the treatment of moderate-to-severe plaque psori …
Psoriasis.
Burfield L, Burden AD. Burfield L, et al. J R Coll Physicians Edinb. 2013;43(4):334-8; quiz 339. doi: 10.4997/JRCPE.2013.414. J R Coll Physicians Edinb. 2013. PMID: 24350319 Review.
Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting 1.3-2.2% of the UK population.1 Most commonly, psoriasis is characterised by well-demarcated, red plaques with adherent scale with a predilection for the scalp and extensor surfaces o …
Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting 1.3-2.2% of the UK population.1 Most commonly, psorias …
Frailty and solid-organ transplant candidates: a scoping review.
Kao J, Reid N, Hubbard RE, Homes R, Hanjani LS, Pearson E, Logan B, King S, Fox S, Gordon EH. Kao J, et al. BMC Geriatr. 2022 Nov 16;22(1):864. doi: 10.1186/s12877-022-03485-7. BMC Geriatr. 2022. PMID: 36384461 Free PMC article. Review.
BACKGROUND: There is currently no consensus as to a standardized tool for frailty measurement in any patient population. In the solid-organ transplantation population, routinely identifying and quantifying frailty in potential transplant candidates would supp …
BACKGROUND: There is currently no consensus as to a standardized tool for frailty measurement in any patient population. In the solid …
Transplant-associated hyperglycemia.
Bloom RD, Crutchlow MF. Bloom RD, et al. Transplant Rev (Orlando). 2008 Jan;22(1):39-51. doi: 10.1016/j.trre.2007.06.001. Transplant Rev (Orlando). 2008. PMID: 18631857 Review.
As patient survival after solid organ transplantation continues to improve, comorbidites associated with chronic hyperglycemia will assume increasing importance in limiting outcomes and quality of life. ...Shared and distinct pathogenic factors and clinical r …
As patient survival after solid organ transplantation continues to improve, comorbidites associated with chronic hyperg …
2,026 results